Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: A case report

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 4, 2011, Pages 643-645

  Kimura, Yutaka ^a   Imasato, Mitsunobu ^b   Yano, Hiroshi ^a   Taniguchi, Hirokazu ^a   Danno, Katsuki ^a   Kanoh, Toshiyuki ^a   Ohnishi, Tadashi ^a   Tono, Takeshi ^a   Nakano, Yoshiaki ^a   Monden, Takushi ^a   Imaoka, Shingi ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Gastric cancer; Paclitaxel resistant

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL;

ADULT; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GASTRECTOMY; HUMAN; ILEUS; MALE; MULTIPLE CYCLE TREATMENT; PERITONEUM METASTASIS; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE;

EID: 79960621036     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70(2): 380-383, 1994.
2. Taguchi T, Sakata Y, Kanamaru R, et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/ recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A) (in Japanese). Jpn J Cancer Chemother 25(12): 1915-1924, 1998.
3. Mai M, Sakata Y, Kanamaru R, et al: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Cooperative Study Group trial (group B) (in Japanese). Jpn J Cancer Chemother 26(4): 487-496, 1999.
4. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32(7): 248-254, 2002. (Pubitemid 43102808)
5. Gligorov J and Lotz JP: Preclinical pharmacology of taxanes: implications of the differences. Oncologist 9(Suppl 2): 3-8, 2004. (Pubitemid 38747838)
6. Hanauske AR, Degen D, Hilsenbeck SG, et al: Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3(2): 121-124, 1992.
7. Untch M, Untch A, Sevin BU, et al: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 5(1): 24-30, 1994. (Pubitemid 24066558)
8. Fromes Y, Gounon P, Veitia R, et al: Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 15(4): 377-388, 1996. (Pubitemid 26242162)
9. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer 1(1): 10-24, 1998.
10. Boku N, Yamamoto S, Shirao K, et al: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). 2007 ASCO Annual Meeting, J Clin Oncol 25(18S): abstr LBA4513.
11. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric can- cer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3): 215-221, 2008.
12. Hironaka S, Zenda S, Boku N, et al: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9(1): 14-18, 2006.
13. Shin E, Ishitobi M, Hiraoia M, et al: Phase I study of docetaxel administrated by bi-weekly infusion to patients with metastatic breast cancer. Anticancer Res 20(6C): 4721-4726, 2000.
14. Vázquez S, Grande C, Amenedo M, et al: Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 15(5): 489-494, 2004. (Pubitemid 38736947)
15. Oishi T, Kigawa J, Fujiwara K, et al: A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 90(2): 421-424, 2003. (Pubitemid 36952038)
16. Ringel I and Horwitz SB: Studies with RP59676 (taxotere): a semisynthetic analogue of taxol. J Nat Cancer Inst 83(4): 288-291, 1991.
17. Valero V, Jones SE, Von Hoff DD, et al: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10): 3362-3368, 1998. (Pubitemid 28481633)
18. Verschraegen CF, Sittisomwong T, Kudelka AP, et al: Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J Clin Oncol 18(14): 2733-2739, 2000. (Pubitemid 30463556)
19. Rose PG, Blessing JA, Ball HG, et al: A phase II study of docetaxel in paditaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88(2): 130-135, 2003. (Pubitemid 36263370)